First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Ready, Neal; D. Hellmann, Matthew; M. Awad, Mark; A. Otterson, Gregory; Gutierrez, Martin; F. Gainor, Justin; Borghaei, Hossein; Jolivet, Jacques; Horn, Leora; Mates, Mihaela; R. Brahmer, Julie; Rabinowitz, Ian; S. Reddy, Pavan; Chesney, Jason; Michael Orcutt, James; R. Spigel, David; Reck, Martin; J. O’Byrne, Kenneth; Paz‐Ares, Luis; Hu, Wenhua; E. Zerba, Kim; Li, Xuemei; Lestini, Brian; J. Geese, William; D. Szustakowski, Joseph; Green, George; Han, Chang; S. Ramalingam, Suresh

doi:10.1200/jco.18.01042

Public

First-Line Nivolumab Plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers

Published in Journal of Clinical Oncology • Feb 20, 2019

Authors:

Neal Ready

Matthew D. Hellmann

Mark M. Awad

Abstract

PURPOSE CheckMate 568 is an open-label phase II trial that evaluated the efficacy and safety of nivolumab plus low-dose ipilimumab as first-line treatment of advanced/metastatic non–small-cell lung cancer (NSCLC). We assessed the association of efficacy with programmed death ligand 1 (PD-L1) express...

Subject

Nivolumab

Medicine

Ipilimumab

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!